Heart valve showdown: intermediate sizing may reduce complications in aortic stenosis

This trial tests whether a newer balloon-expandable heart valve with intermediate sizes (Myval) is as safe as a standard self-expanding valve (Evolut) in people with severe aortic stenosis whose valve measurements fall in a 'borderline' range. About 600 participants will be randomly assigned to receive one of the two valves during a routine transcatheter aortic valve replacement (TAVI). The study will track safety events like death, stroke, bleeding, and need for a pacemaker within 30 days, and follow patients for up to 5 years to see how well the valve works over time.